background
urin
amongst
frequent
specimen
submit
clinic
microbiolog
laboratori
mani
neg
uropathogen
day
report
urin
neg
bacteria
wbc
could
impact
inappropri
antimicrobi
use
well
day
report
presenc
bacteriawbc
may
influenc
decis
regard
empir
antimicrobi
therapi
evalu
flow
cytometri
urin
submit
cultur
suscept
test
method
urin
submit
clinic
microbiolog
royal
univers
hospit
saskatoon
sk
canada
use
raw
boric
acid
preserv
urin
includ
evalu
inpati
outpati
approxim
ml
urin
place
separ
tube
flow
cytometri
perform
twice
specimen
urin
inocul
tryptic
soy
agar
contain
sheep
red
blood
cell
macconkey
agar
incub
hour
cultur
result
correl
bacteri
wbc
count
flow
cytometri
read
result
total
urin
analyz
preserv
raw
raw
urin
bacteri
cellsul
wbcul
fc
bacteri
cellsul
wbcul
urin
growth
mix
cultur
urin
million
bacteri
similar
result
seen
preserv
urin
preserv
urin
growth
mix
cultur
urin
million
bacteri
conclus
screen
urin
use
flow
cytometri
potenti
identifi
urin
requir
cultur
day
report
neg
cut
correl
insignific
coloni
count
urin
cultur
higher
cut
would
reduc
number
urin
cultur
laboratori
process
approxim
urin
per
year
possibl
day
report
neg
influenc
workload
work
flow
like
posit
impact
antimicrobi
stewardship
program
current
implement
technolog
os
use
malditof
select
gene
rrna
gene
gyrb
gene
sequenc
practic
accur
identifi
clinic
import
viridan
group
streptococci
background
clinic
signific
viridan
group
streptococci
vg
identif
import
problemat
particular
streptococcu
miti
group
malditof
ms
practic
clinic
identif
problemat
speci
select
gene
sequenc
necessari
order
make
identif
reliabl
studi
investig
perform
malditof
ms
system
vg
identif
method
use
rrna
gene
gyrb
gene
sequenc
gold
standard
perform
two
malditof
ms
instrument
identif
vg
clinic
isol
studi
result
bruker
biotyp
vitek
ms
ivd
system
correctli
identifi
isol
respect
vitek
ms
ruo
system
least
reliabl
correctli
identifi
isol
speci
level
sever
misidentif
invalid
result
bruker
biotyp
system
unreli
identif
speci
within
miti
group
among
nonpneumococci
isol
mitiss
oraliss
pseudopneumonia
biotyp
misidentifi
pneumonia
lead
low
sensit
low
posit
predict
valu
speci
contrast
vitek
ms
ivd
demonstr
better
resolut
pneumococci
nonpneumococci
despit
inabl
distinguish
mitiss
orali
conclus
accur
specieslevel
identif
improv
vg
spectra
databas
need
base
malditof
analysi
select
rrna
gene
plu
gyrb
gene
sequenc
design
practic
vg
identif
algorithm
background
enterococcu
speci
gramposit
facult
anaerob
oval
cocci
part
natur
microbiota
gastrointestin
tract
human
emerg
lead
caus
healthcareassoci
infect
also
caus
wide
rang
communityassoci
infect
among
enterococc
infect
e
faecali
e
faecium
encount
speci
account
clinic
isol
remain
caus
speci
e
avium
e
casseliflavu
e
gallinarum
e
hira
e
raffinosu
method
multiplex
pcr
assay
develop
different
frequent
encounterd
enterococcu
speci
thirteen
strain
includ
e
avium
obtain
american
type
cultur
collect
use
refer
strain
clinic
isol
enterococci
collect
nation
taiwan
univers
hospit
kaohsiung
medic
univers
hospit
result
multiplex
pcr
assay
one
forward
primer
seven
speciesspecif
revers
primer
design
base
determin
groel
sequenc
expect
size
amplicon
bp
e
avium
bp
e
casseliflavu
bp
e
faecali
bp
e
faecium
bp
e
gallinarum
bp
e
hira
bp
e
raffinosu
refer
strain
clinic
isol
test
yield
expect
amplicon
size
specificc
multiplex
pcr
test
enterococcu
speci
includ
e
cecorum
e
duran
e
mundtii
none
bacteri
speci
gener
product
similar
size
seven
enterococcu
speci
conclus
simpl
multiplex
pcr
assay
basi
groel
gene
provid
altern
way
identifi
clinic
import
enterococcu
speci
os
comparison
first
void
urin
urethr
swab
detect
ureaplasma
male
patient
urogenit
infect
use
cultur
sequenc
isotherm
rna
amplif
assay
background
studi
design
evalu
urin
urethr
swab
detect
ureaplasma
male
patient
urogenit
infect
use
cultur
cultur
sequenc
isotherm
rna
amplif
assay
iraa
rrna
method
total
nondupl
male
patient
urogenit
infect
includ
randomli
divid
urin
group
n
urethr
swab
group
n
urin
specimen
split
duplic
parallel
aliquot
test
cultur
cultur
sequenc
iraa
urethr
swab
detect
cultur
cultur
togeth
sequenc
respect
result
posit
rate
ureaplasma
two
group
p
respect
urin
group
compar
cultur
sequenc
sensit
specif
iraa
respect
cultur
respect
urethr
swab
group
compar
cultur
sequenc
sensit
specif
cultur
respect
ureaplasma
posit
specimen
contain
u
parvum
contain
u
urealyticum
contain
furthermor
among
ureaplasma
posit
specimen
ciprofloxacin
ofloxacin
show
lowest
vitro
activ
conclus
data
suggest
urin
highli
consist
urethr
swab
detect
ureaplasma
male
patient
urogenit
infect
cultur
reliabl
method
higher
specif
even
better
iraa
os
creactiv
protein
level
differ
common
respiratori
viral
infect
role
pointofcar
test
detect
influenza
infect
epidem
dengu
involv
sever
dengu
case
occur
certain
year
area
global
epidemiolog
also
show
specif
strain
genotyp
serotyp
dengu
virus
denv
increas
epidem
sever
therefor
studi
aim
better
defin
epidem
potenti
denv
epidemiolog
virolog
immunolog
character
worthwhil
pursu
futur
predict
epidem
sever
isol
strain
patient
present
clinic
mild
dengu
fever
df
versu
sever
dengu
hemorrhag
fever
dhf
case
differ
epidemiolog
condit
eg
tempor
spatial
attribut
epidem
citi
better
monitor
dynam
viral
genet
phenotyp
chang
epidem
process
addit
differ
clade
viral
sequenc
variat
isol
variou
time
point
use
spatial
analys
viral
spread
reproduct
number
dhf
case
appear
mostli
climb
peak
time
dengu
case
tempor
spatial
evolut
epidem
southern
taiwan
interestingli
variat
occur
differ
day
onset
dengu
ill
patient
microlevel
well
differ
time
period
epidem
macrolevel
popul
dynam
moreov
differ
isol
viral
sequenc
variat
differ
viral
growth
kinet
viral
transmiss
spatial
spread
epidemiolog
condit
import
immun
statu
primari
secondari
denv
infect
drive
forc
associ
viral
chang
sever
dengu
case
particularli
area
low
incid
dengu
previou
year
taiwan
area
dengueendem
provid
valuabl
opportun
integr
clinic
epidemiolog
viral
immunolog
find
timedepend
denv
isol
gener
causal
infer
fulli
understand
mechan
increas
epidem
sever
particularli
import
monitor
denv
viral
chang
intern
collabor
genotyp
greater
intercountri
spread
mortal
vitro
antifung
suscept
test
afst
provid
inform
hint
clinic
drug
use
predict
outcom
treatment
certain
extent
purpos
studi
determin
antifung
suscept
profil
clinic
aspergillu
isol
two
center
taiwan
mainland
china
activ
antifung
drug
usual
use
contribut
knowledg
prevail
antifung
resist
pattern
aspergillu
two
differ
center
method
perform
vitro
afst
genet
confirm
aspergillu
isol
repres
differ
speci
collect
variou
clinic
sourc
activ
antifung
drug
amphotericin
b
triazol
echinocandin
use
sensititr
yeaston
commerci
avail
altern
clinic
laboratori
standard
institut
microdilut
method
aspergillu
analyz
suscept
profil
accord
gener
minimum
inhibitori
concentr
mic
minimum
effect
concentr
mec
interpret
code
differ
antifung
resist
pattern
two
center
aspergillu
isol
also
compar
result
total
test
aspergillu
isol
show
entir
suscept
profil
test
antifung
fairli
low
mic
mec
isol
differ
aspergillu
speci
show
resist
one
two
class
antifung
drug
amphotericin
b
resist
predomin
problem
isol
show
reduc
suscept
rate
two
fumigatu
isol
resist
triazol
discov
one
resist
voriconazol
mic
itraconazol
mic
triazol
crossresist
isol
found
echinocandin
highli
potent
aspergillu
isol
test
distinct
differ
resist
profil
observ
two
center
isol
except
flavu
mailand
china
show
higher
resist
rate
amphotericin
b
taiwan
conclus
identifi
antifung
suscept
profil
clinic
aspergillu
isol
two
center
taiwan
mainland
china
sever
resist
pattern
discov
among
differ
aspergillu
speci
potent
vitro
activ
triazol
echinocandin
studi
indic
two
class
antifung
agent
clinic
import
role
treatment
aspergillu
infect
clinic
use
amphotericin
b
done
cautious
especi
flavu
encount
background
candidemia
fourth
common
bloodstream
infect
hospit
patient
mortal
rate
high
pitt
bacteremia
score
pb
highli
correl
mortal
patient
bacteremia
howev
simplifi
valid
predict
rule
prognosi
candidemia
object
explor
better
score
system
predict
prognosi
method
review
medic
record
patient
cultureproven
candidemia
diagnos
nagasaki
univers
hospit
japan
use
multivari
logist
regress
model
identifi
prognost
factor
result
total
patient
enrol
median
age
year
old
sevenday
thirtyday
mortal
rate
respect
factor
associ
mortal
candidemia
patient
univari
analysi
acut
kidney
injuri
includ
hemodialysi
akihd
remov
central
venou
cathet
cvc
within
hour
pb
patient
back
ground
includ
diabet
mellitu
use
immunosuppress
neutropenia
base
result
formul
modifi
pb
mpb
replac
evalu
item
bodi
temperatur
pb
akihd
factor
associ
mortal
multivari
analysi
shown
tabl
background
aspergillu
terreu
common
soil
saprophyt
also
clinic
import
caus
infect
rang
superfici
infect
onychomycosi
invas
aspergillosi
ia
sever
immunocompromis
host
endophthalm
caus
terreu
rare
report
literatur
report
case
endogen
endophthalm
caus
terreu
nonimmunocompromis
patient
hypertens
take
regular
medic
blood
pressur
control
normal
rang
without
prior
intraocular
eye
surgeri
histori
immunosuppress
method
vitreou
biopsi
taken
cultur
direct
smear
microscopi
identifi
isol
cultur
posit
plate
phenotyp
observ
molecular
method
vitro
antifung
suscept
test
done
etest
result
fungal
spore
septat
hypha
found
vitreou
direct
smear
figur
tini
hairlik
coloni
grew
sda
day
cultur
coloni
morpholog
still
atyp
day
cultur
figur
found
attach
spore
use
scotch
tape
stick
coloni
side
figur
time
gener
nearli
month
strain
show
typic
coloni
figur
microscop
morpholog
figur
isol
final
identifi
terreu
accord
morpholog
result
phenotyp
molecular
identif
isol
mic
itraconazol
voriconazol
amphotericin
b
respect
conclus
earli
diagnost
therapeut
vitrectomi
use
obtain
suffici
sampl
organ
identif
also
reduc
organ
load
inflammatori
mediat
eye
time
report
result
direct
smear
clinic
physician
meaning
initi
select
antimicrobi
agent
phenotyp
atyp
clinic
import
filament
fungi
use
sequenc
analysi
molecular
identif
method
help
identifi
fungal
pathogen
promptli
background
increas
incid
invas
candidemia
coincid
increas
number
sever
immunosuppress
patient
even
though
new
drug
present
develop
resist
antifung
drug
becom
increasingli
alarm
especi
patient
requir
longterm
treatment
prophylaxi
better
understand
awar
shift
flora
moreresist
speci
clinic
impact
antifung
drug
resist
essenti
improv
treatment
outcom
studi
report
resist
azol
echinocandin
among
candida
speci
method
assess
presenc
candida
isol
associ
bloodstream
infect
januari
decemb
resist
profil
evalu
measur
mic
fluconazol
voriconazol
micafungin
interpret
breakpoint
defin
guidelin
clinic
laboratori
standard
institut
clsi
result
total
episod
candidemia
recogn
candida
parapsilosi
account
candida
albican
candida
tropicali
candida
glabrata
candida
famata
other
gender
dispar
male
femal
patient
admit
critic
care
age
rang
day
yearold
candida
strain
suscept
antifung
drug
micafungin
hand
isol
resist
voriconazol
although
azol
well
fluconazol
highest
level
resist
increas
tendenc
resist
level
conclus
echinocandin
micafungin
exhibit
excel
vitro
suscept
candida
strain
therebi
appropri
use
critic
ill
patient
longterm
treatment
patient
requir
prophylact
antifung
drug
differ
antifung
resist
among
candida
strain
isol
hospit
emphas
import
local
surveil
program
influenc
select
therapeut
manag
atrisk
patient
impact
biofilm
format
breakthrough
candidemia
li
weisin
lee
chenhsiang
divis
infecti
diseas
kaohsiung
chang
gung
memori
hospit
chang
gung
univers
kaohsiung
background
candidemia
often
contribut
poor
prognosi
patient
persist
breakthrough
one
common
complic
candidemia
occurr
candidemia
patient
receiv
antifung
therapi
least
breakthrough
candidemia
brc
report
increasingli
biofilm
mainli
compos
sessil
cell
extracellular
matrix
initi
adher
freemov
plankton
cell
surfac
human
endothelium
medic
implant
lead
difficulti
erad
microorgan
blood
conduct
studi
analyz
risk
brc
emphas
impact
biofilm
format
method
retrospect
studi
includ
adult
patient
candidemia
receiv
repeat
blood
cultur
studi
least
first
episod
candidemia
admit
kaohsiung
chang
gung
memori
hospit
januari
decemb
match
propens
score
candida
speci
enrol
patient
divid
two
group
without
brc
evalu
risk
factor
brc
clinic
outcom
result
total
patient
includ
studi
brc
sixtyeight
patient
match
basi
propens
score
candida
spice
group
candida
strain
high
biofilm
former
p
treatment
azol
p
inappropri
treatment
within
h
blood
cultur
collect
p
includ
resist
initi
antifung
agent
p
suboptim
dose
initi
antifung
agent
p
significantli
associ
brc
multivari
analysi
patient
central
venou
cathet
diagnosi
ci
p
stain
higher
biofilm
former
ci
p
patient
receiv
suboptim
dose
initi
antifung
agent
ci
p
independ
associ
brc
compar
candid
strain
nonbrc
group
biofilm
former
significantli
higher
candida
albican
c
tropicali
c
glabrata
brc
group
signific
differ
overal
mortal
durat
hospit
group
conclus
high
biofilm
former
presenc
central
cathet
suboptim
dose
initi
antifung
agent
relat
brc
biofilm
former
c
albican
c
tropicali
c
glabrata
significantli
higher
brc
group
data
suggest
biofilm
play
major
role
develop
breakthrough
candidemia
background
antiherpet
drug
acyclovir
valaciclovir
penciclovir
famciclovir
phosphoryl
viral
thymidin
kinas
termin
dna
synthesi
amenamevir
foscavir
directli
inhibit
viral
helicaseprimas
dna
polymeras
respect
inhibit
replic
herp
simplex
viru
hsv
varicellazost
viru
acyclovir
acv
well
foscavir
differ
mode
action
inhibitori
mode
viral
replic
character
appear
drug
action
time
drug
addit
mainten
antivir
action
method
suppress
hsv
replic
effici
acv
inhibitori
concentr
plaqu
format
treatment
start
h
infect
total
incub
h
result
viru
replic
monitor
presenc
drug
pfa
inhibit
replic
hsv
inhibit
acyclovir
h
viru
yield
gradual
increas
similar
level
inhibit
acv
pfa
inhibit
viral
replic
presenc
hour
infect
acyclovir
allow
although
viru
yield
viral
dna
copi
number
control
without
drug
viru
replic
presenc
acyclovir
time
less
effici
infect
per
viral
dna
copi
absenc
antivir
agent
indic
viru
impair
dna
antivir
activ
influenc
replic
phase
infect
acv
much
reduc
late
phase
infect
conclus
antivir
concentr
maintain
sigl
dose
antivir
activ
influenc
replic
cycl
contrast
valaciclovir
viral
helicaseprimas
inhibitor
show
prefer
profil
antiherpet
agent
better
pharmacokinet
profil
acyclovir
thu
ideal
profil
open
new
era
antiherpet
therapi
herp
simplex
viru
infect
herp
zoster
result
physic
examin
normal
except
disorient
loss
vigor
laboratori
data
exept
low
level
slight
elev
crp
normal
cryptococc
antigen
elev
toxoplasma
igg
igm
neg
plain
head
ct
scan
gadoliniumenhanc
head
mri
reveal
brain
edema
three
mass
frontal
occipit
lobe
might
induc
cryptococcu
spp
bacteria
immun
reconstitut
inflammatori
syndrom
iri
lymphoma
strongli
suspect
multipl
lesion
decreas
likelihood
gadoliniumenhanc
mri
shown
lesion
month
prior
could
nt
perform
lumbar
punctur
risk
brain
herniat
start
amphotericin
b
flucytosin
cryptococc
infect
ceftriaxon
metronidazol
teicoplanin
possibl
bacteri
abscess
hospit
day
hd
conscious
deterior
head
ct
show
worsen
brain
edema
neurosurgeon
perform
small
craniotomi
decreas
intracrani
pressur
unabl
suffici
aspir
abscess
hd
fever
increas
gram
stain
brain
detect
bacteria
dexamethason
mgkgday
po
initi
case
iri
brain
biopsi
turn
dlbcl
standard
therapi
intracrani
dlbcl
radiat
highdos
methotrex
possibl
given
patient
condit
therefor
whole
brain
radiat
perform
howev
patient
condit
improv
die
hd
conclus
among
patient
chronic
respiratori
diseas
seroposit
statu
directli
translat
protect
influenza
infect
howev
higher
rate
serum
antibodi
influenza
virus
hcw
also
indic
group
repeatedli
expos
virus
suggest
greater
risk
acquir
infect
case
outbreak
graver
concern
transmit
vulner
patient
background
zika
viru
discov
belong
flaviviru
famili
drawn
much
attent
world
wide
outbreak
shown
viru
caus
neurolog
disord
syndrom
acut
myeliti
adult
microcephali
newborn
children
zika
viral
proteas
two
compon
serin
proteas
requir
matur
viral
protein
make
attract
target
made
three
distinct
zika
proteas
construct
ezipro
bzipro
gzipro
structur
function
studi
xray
crystallographi
thermal
shift
assay
nmr
spectroscopi
use
character
structur
proteas
construct
give
rise
insight
structurebas
inhibitor
design
result
zika
proteas
demonstr
close
conform
regardless
inhibitorsubstr
bind
crystal
structur
zika
proteas
complex
ackraldehyd
ic
nm
also
determin
ntermin
cap
region
aldehyd
import
bind
nmr
studi
confirm
bind
mode
solut
titrat
peptid
substrat
differ
length
reveal
ntermin
cap
also
requir
bind
peptid
without
aldehyd
group
bind
proteas
conclus
proteas
construct
bzipro
cofactor
region
proteas
region
coexpress
suitabl
studi
proteas
inhibitor
interact
artifici
glycin
linker
use
convent
construct
may
affect
proteas
dynam
solut
dipeptid
inhibitor
ackraldehyd
potent
proteas
inhibitor
challeng
still
remain
clinic
applic
due
charg
fragmentbas
drug
discoveri
may
provid
way
develop
potent
proteas
inhibitor
background
hepat
b
c
seen
higher
popul
among
hemodialysi
patient
parenter
transmiss
common
rout
hemodialysi
unit
nearli
patient
screen
antihcv
hbsag
oftenli
use
despit
prevent
method
devic
separ
cross
infect
occur
occult
infect
hepat
b
c
viru
diagnos
standard
laboratori
screen
test
detect
hbv
dna
absenc
hbsag
antigen
serum
call
occult
hepat
b
infect
obi
detect
hcvrna
mononuclear
cell
peripher
blood
absenc
antihcv
hcv
rna
serum
call
occult
hepat
c
infect
oci
aim
diagnos
obi
oci
rate
hemodialysi
patient
provinc
canakkal
turkey
method
hbsag
antihcv
neg
normal
alanin
amino
transpheras
alt
valu
includ
studi
demograph
data
caus
renal
failur
hemodialysi
method
durat
alt
valu
hepat
marker
record
previou
patient
file
patient
studi
group
consist
object
serum
antihbc
igg
valu
investig
enzymelink
immunosorb
assay
elisa
architecht
abbott
usa
hbv
dna
serum
hcv
rna
mononuclear
cell
investig
real
time
pcr
method
result
mean
age
patient
year
old
mean
dialysi
period
month
nearli
patient
arterioven
fistula
mean
alt
level
iu
ml
normal
rang
iuml
total
antihbc
posit
found
number
hbv
dna
posit
antihbc
ig
g
neg
patient
four
alon
antihbc
posit
detect
serum
detect
hbv
dna
obi
observ
patient
patient
antihb
posit
mean
antihb
titer
miuml
could
detect
hcv
rna
either
serum
mononuclear
cell
oci
rate
zero
studi
group
conclus
turkey
hbsag
posit
anti
hcv
posit
hbsag
anti
hcv
posit
rate
seroneg
hbsag
neg
anti
hcv
neg
patient
report
viral
serolog
profil
examin
hemodialysi
patient
usual
oci
rate
higher
obi
among
hemodialysi
patient
obi
may
detect
even
rare
think
prevent
transmiss
hbv
infect
enough
investig
exist
virus
routin
serolog
test
os
urinari
concentr
bactericid
activ
tobramycin
healthi
subject
receiv
singl
oral
dose
milligram
maria
loos
kurt
naber
paul
shield
harald
reinhart
florian
wagenlehn
justusliebig
univ
giessen
giessen
germani
technic
univ
munich
straub
germani
enteri
biopharma
inc
boonton
nj
allphas
pharma
consult
llc
amman
jordan
background
phase
clinic
studi
perform
assess
pharmacokinet
safeti
oral
form
tobramycin
multipl
ascend
dose
healthi
subject
ex
vivo
studi
present
urinari
concentr
uc
bactericid
activ
tobramycin
subset
method
urin
healthi
subject
collect
hour
h
oral
administr
mg
tobramycin
formul
improv
absorpt
uc
determin
lcmsm
method
urinari
bactericid
titer
ubt
determin
five
test
strain
minim
inhibitori
bactericid
concentr
micmbc
test
strain
determin
cationadjust
muellerhinton
broth
camhb
pool
blank
urin
mbc
subject
differ
ph
result
median
uc
tobramycin
mgl
individu
urin
ph
rang
micmbc
mgl
tobramycin
test
strain
escherichia
coli
atcc
mgl
e
coli
mgl
klebsiella
pneumonia
mgl
proteu
mirabili
mgl
pseudomona
aeruginosa
mgl
blank
urin
mbc
mgl
mgl
strain
ph
ph
e
coli
atcc
mgl
e
coli
mgl
k
pneumonia
mgl
p
mirabili
mgl
p
aeruginosa
mgl
median
ubt
valu
collect
period
h
e
coli
atcc
e
coli
k
pneumonia
p
mirabili
p
aeruginosa
strain
least
ubt
reach
subject
except
ubt
subject
p
aeruginosa
strain
conclus
new
enteri
formul
oral
tobramycin
significantli
improv
poor
absorpt
standard
tobramycin
salt
singl
dose
mg
oral
tobramycin
posit
ubt
could
reach
strain
highest
titer
observ
collect
period
hour
subject
hour
administr
pathogen
test
concentr
tobramycin
urin
least
two
time
urinari
mbc
averag
urinari
mbc
present
hour
therefor
bid
tid
dosag
regimen
may
suitabl
test
treatment
urinari
tract
infect
clinic
studi
sinc
activ
tobramycin
higher
alkalin
acid
urin
alkal
comed
could
improv
urinari
bactericid
activ
os
effect
toxin
product
antibiot
multidrugresist
streptococcu
pyogen
masaaki
minami
ryoko
sakakibara
mika
watanab
hideo
morita
naoto
kanemaki
depart
bacteriolog
nagoya
citi
univers
depart
clinic
investig
daido
hospit
depart
gastroenterolog
daido
hospit
background
streptococcu
pyogen
caus
sever
seriou
diseas
cellul
sepsi
necrot
fasciiti
although
rel
sensit
antibiot
clindamycin
tetracyclin
levofloxacinresist
streptococcu
pyogen
emerg
recent
although
mani
research
pay
attent
antimicrobi
suscept
pattern
antibiogram
research
concern
antibiot
affect
toxinproduct
drugresist
streptococcu
pyogen
focu
antibiot
induc
toxinproduct
multidrugresist
streptococcu
pyogen
method
multidrugresist
clindamycin
tetracyclin
levofloxacinresist
streptococcu
pyogen
isol
daido
hospit
japan
clinic
isol
confirm
vitek
ii
system
antibioticresist
pattern
mic
determin
etest
accord
clsi
recommend
bacteria
preincub
sheep
blood
agar
hour
adjust
cfu
incub
todd
hewitt
broth
clindamycin
tetracyclin
levofloxacin
respect
adequ
time
point
measur
turbid
od
nm
bacteri
cultur
growth
analysi
hour
analyz
dnase
activ
hemolysi
assay
use
bacteri
cultur
result
mic
clindamycin
tetracyclin
levofloxacin
bacteria
respect
differ
growth
antibiot
treat
untreat
bacteria
dnase
hemolysi
activ
levofloxacininduc
bacteria
signific
greater
antibioticuntr
bacteria
dnase
hemolysi
activ
clindamycininduc
bacteria
slightli
greater
antibioticuntr
bacterium
tetracyclin
affect
dnase
hemolysi
activ
bacteria
significantli
conclus
studi
show
differ
toxin
product
even
antibioticresist
bacteria
depend
type
antibacteri
agent
result
also
reveal
levofloxacininduc
toxin
product
drugresist
streptococcu
pyogen
background
pseudomona
aeruginosa
gramneg
bacterium
commonli
implic
nosocomi
infect
also
associ
resist
multipl
firstlin
antimicrobi
agent
ceftolozanetazobactam
new
antimicrobi
combin
approv
fda
treatment
infect
due
p
aeruginosa
detect
ceftolozanetazobactam
resist
clinic
isol
examin
possibl
underli
mechan
method
bloodstream
isol
p
aeruginosa
screen
multidrug
resist
select
isol
subject
suscept
test
secondari
antimicrobi
agent
panel
etest
clonal
uniqu
confirm
pulsedfield
gel
electrophoresi
pfge
hydrolyt
activ
crude
cell
lysat
assess
use
spectrophotometr
assay
nitrocefin
substrat
normal
total
protein
content
p
aeruginosa
atcc
clinic
isol
known
harbor
use
control
singl
nucleotid
polymorph
snp
analysi
whole
genom
sequenc
undertaken
provid
addit
insight
resist
mechan
read
select
isol
map
genom
refer
strain
variant
identifi
gatk
samtool
clc
genom
workbench
select
annot
snpeff
result
bloodstream
isol
screen
resist
ceftolozanetazobactam
preval
specif
identifi
pair
isol
patient
index
isol
suscept
ceftolozanetazobactam
mic
mgl
anoth
isol
recov
day
later
mutant
resist
mic
mgl
similar
suscept
profil
also
seen
ceftazidimeavibactam
isol
clonal
similar
pfge
normal
hydrolyt
activ
found
approxim
higher
mutant
isol
whole
genom
sequenc
reveal
mutat
gene
predict
encod
daladala
carboxypeptidas
dacb
ampd
ampc
resist
isol
conclus
ceftolozanetazobactam
resist
p
aeruginosa
could
mediat
via
overexpress
betalactamas
eg
ampc
background
antibiot
resist
becom
global
health
threat
due
rapid
evolut
multidrug
resist
pathogen
bacteria
well
shortag
avaibil
altern
treat
bacteri
infect
especi
gramneg
bacteria
robenidin
current
regist
anim
coccidiostat
shown
bactericid
activ
gramposit
organ
includ
methicillinresist
staphylococcu
aureu
analogu
screen
undertaken
show
best
activ
initi
screen
test
agsint
two
mrsa
two
e
coli
isol
mic
rang
meanwhil
two
compound
also
demonstr
excel
bactericid
activ
accord
minimum
bactericid
concentr
test
gramneg
bacteria
achiev
reduct
coloni
form
unit
within
minut
mic
select
e
coli
strain
method
minimum
inhibitori
concentr
minimum
bactericid
concentr
timekil
kinet
assay
use
evalu
efficaci
pharmacodynam
human
pathogen
isol
e
coli
enterobact
aerogen
enterobact
cloaca
klebsiella
oxytoca
klebsiella
pneumonia
anim
pathogen
isol
expec
etec
vitro
toxic
profil
creat
use
cell
cytotox
assay
varieti
eukaryot
cell
line
synergist
antagonist
effect
efflux
pump
inhibitor
conjunct
compound
examin
use
checkerboard
method
result
compound
demonstr
antimicrobi
activ
rang
human
veterinari
pathogen
low
concentr
mic
mic
ml
activ
bacteriostat
sustain
overa
hour
period
compound
much
lower
mic
e
coli
lack
drug
efflux
pump
acrb
mic
wild
type
e
coli
significantli
lower
presenc
efflux
pump
inhibitor
sdspage
also
show
resist
sensit
klebsiella
isol
differ
cell
membran
protein
composit
conclus
power
bactericid
activ
gramneg
bacteria
efflux
pump
substrat
therefor
usag
efflux
pump
inhibitor
combin
ncl
may
increas
activ
gramneg
bacteria
result
suggest
compound
deriv
potenti
develop
novel
antimicrobi
therapi
humanveterinari
gramneg
pathogen
os
high
vitro
activ
kpcproduc
enterobacteriacea
china
qiwen
yang
ge
zhang
zhipeng
xu
yingchun
xu
peke
union
medic
colleg
hospit
peke
union
medic
colleg
chines
academi
medic
scienc
beij
china
background
purpos
studi
evalu
activ
meropenem
combin
novel
betalactamas
inhibitor
enterobacteriacea
isol
produc
kpc
serinecarbapenemas
collect
chines
hospit
method
total
kpcproduc
enterobacteriacea
collect
chines
hospit
locat
provinc
year
evalu
bacteria
identifi
peke
union
medic
colleg
hospit
malditof
ms
method
combin
test
checkerboard
configur
well
panel
accord
moodi
procedur
clinic
microbiolog
procedur
handbook
minimum
inhibitori
concentr
mic
antimicrobi
agent
determin
use
brothmicrodilut
method
follow
clinic
laboratori
standard
institut
clsi
guidelin
ambler
b
c
group
encod
gene
screen
pcr
sequenc
express
level
acrb
gene
kpneumonia
strain
evalu
reversetranscript
realtim
pcr
rpob
gene
use
intern
refer
gene
express
level
acrb
gene
select
clinic
isol
compar
kpneumonia
strain
express
level
gene
clinic
isol
compar
k
pneumonia
strain
result
panel
kpcproduc
strain
highli
resist
meropenem
alon
meropenem
mic
vari
strain
strain
mic
mic
meropenem
alon
addit
result
dosedepend
reduct
meropenem
mic
mic
decreas
presenc
respect
maxim
reduct
mic
observ
mic
decreas
presenc
respect
maxim
reduct
mic
observ
ml
thirteen
k
pneumonia
isol
belong
clone
select
investig
relationship
resist
level
meropenem
plu
mem
rpx
gene
express
level
acrb
gene
strain
meropenem
mic
ugml
decreas
express
found
gene
compar
strain
increas
express
found
acrb
notic
obviou
correl
mem
rpx
high
mic
singl
gene
express
howev
isol
high
mem
rpx
mic
tend
express
andor
loss
conclus
addit
result
dosedepend
reduct
meropenem
mic
kpcproduc
carbapenemresist
enterobacteriacea
high
express
andor
porin
loss
may
relat
high
mem
rpx
mic
requir
investig
os
molecular
character
extend
spectrum
betalactamaseproduc
gramneg
uropathogen
specialist
hospit
north
western
nigeria
tanko
nuhu
bolaji
rebecca
olajumok
olayinka
busayo
olalekan
depart
pharmaceut
pharmaceut
microbiolog
usmanu
danfodiyo
univers
sokoto
nigeria
depart
pharmaceut
pharmaceut
microbiolog
ahmadu
bello
univers
zaria
nigeria
background
extend
spectrum
betalactamas
esbl
produc
enterobacteroacea
fast
becom
lead
aetiolog
agent
antibiot
resist
infect
studi
determin
preval
genet
profil
esblproduc
uropathogen
among
member
famili
enterobacteriacea
method
total
midstream
urin
sampl
collect
period
month
studi
isol
identifi
use
microgen
identif
kit
gnid
suscept
test
perform
use
modifi
kirbi
bauer
method
result
interpret
accord
clinic
laboratori
standard
institut
clsi
esbl
product
detect
doubl
disc
synergi
test
ddst
molecular
character
esbl
posit
isol
confirm
pcr
method
result
total
gram
neg
uropathogen
isol
urin
sampl
isol
made
e
coli
salmonella
arizona
klebsiella
oxytoca
enterobact
gergovia
citrobact
freundii
serratia
marscens
klebsiella
pnuemonia
proteu
mirabili
enterobact
aerogen
edwardsiella
tarda
acinetobact
lwoffi
burkholderia
pseudomallei
pseudomona
aeruginosa
antibiot
suscept
profil
isol
commonli
prescrib
antibiot
use
treatment
utiassoci
infect
show
isol
resist
cotrimoxazol
nalidix
acid
ciprofloxacin
norfloxacin
gentamicin
amoxicillinclavulan
nitrofurantoin
majoriy
isol
multidrug
resist
extens
drug
resist
xdr
pandrug
resist
pdr
fall
classif
pcr
genom
dna
mdresblproduc
isol
show
blactxm
blaoxa
conclus
preval
esbl
studi
molecular
character
select
mdresblproduc
isol
show
harbor
blactxm
gene
blaoxa
gene
os
implement
antibiot
stewardship
program
tunisian
teach
hospit
adnen
toumi
ikbel
kooli
abir
aouam
hajer
ben
brahim
chawki
loussaief
moham
chakroun
infecti
diseas
depart
monastir
univers
hospit
tunisia
background
past
decad
antimicrobi
resist
emerg
major
healthcar
concern
impact
antimicrobi
stewardship
program
asp
reduc
inappropri
antimicrobi
use
prove
asp
implement
tunisia
one
first
asp
implement
hospit
object
describ
take
stock
asp
method
observ
studi
carri
fattouma
bourguiba
hospit
monastir
tunisia
univers
teach
hospit
bed
juli
march
antimicrobi
stewardship
request
receiv
respons
collect
standard
record
result
collect
antimicrobi
stewardship
request
averag
request
per
month
request
came
mainli
emerg
depart
n
orthoped
depart
n
viscer
surgeri
depart
n
physician
solicit
asp
team
senior
case
request
antibiot
therapi
case
need
hospit
case
diagnost
assist
case
need
modifi
antibiot
therapi
initi
case
stop
case
antimicrobi
stewardship
activ
requir
displac
case
case
request
given
medic
record
stewardship
action
modifi
antibiot
therapi
case
start
antibiot
case
action
taken
case
conclus
result
show
great
request
antimicrobi
stewardship
intervent
made
possibl
start
modifi
antibiot
therapi
half
case
confirm
import
reinforc
antimicrobi
stewardship
activ
hospit
os
impact
earli
antibiot
therapi
eat
outcom
patient
sepsi
emerg
room
nation
kidney
transplant
institut
iren
rosellen
p
tan
myrna
mendoza
nation
kidney
transplant
institut
east
avenu
diliman
quezon
citi
philippin
background
surviv
sepsi
campaign
publish
last
earli
goaldirect
therapi
egdt
recommend
emphas
specif
bundl
care
includ
antibiot
administr
within
first
hour
sepsi
recognit
collect
blood
cultur
prior
antibiot
initi
year
sever
foreign
multicent
trial
challeng
recommend
contrast
result
local
studi
determin
complianc
specif
recommend
applic
local
set
reason
studi
conceptu
method
retrospect
cohort
studi
includ
patient
er
diagnos
sepsi
sever
sepsi
septic
shock
base
standard
definit
patient
group
base
time
antibiot
initi
sepsi
recognit
follow
group
earli
antibiot
therapi
eat
group
within
hour
control
group
hour
primari
outcom
inhospit
mortal
timetoantibiot
extract
blood
cultur
prior
antibiot
secondari
outcom
includ
length
hospit
stay
use
vasopressor
mechan
ventil
develop
sepsisrel
complic
p
valu
consid
signific
detect
differ
group
result
twohundr
sixtyon
patient
includ
overal
mortal
rate
overal
mean
timetoantibiot
hour
timetoblood
cultur
hour
averag
timetoantibiot
hour
eat
control
group
respect
mortal
significantli
higher
control
group
vs
p
sepsisrel
complic
patient
eat
group
develop
acut
kidney
injuri
p
acut
respiratori
failur
p
significantli
increas
control
group
conclus
earli
initi
antibiot
therapi
within
hour
sepsi
recognit
demonstr
decreas
mortal
risk
time
antibiot
collect
blood
cultur
delay
compar
current
recommend
among
sepsisrel
complic
prolong
timetoantibiot
hour
associ
develop
acut
respiratori
failur
subsequ
need
mechan
ventil
complianc
guidelin
appropri
antimicrobi
prescrib
australian
hospit
rodney
jame
kirsti
buis
karin
thurski
nation
centr
antimicrobi
stewardship
peter
doherti
institut
infect
immun
melbourn
vic
background
hospit
nation
antimicrobi
prescrib
survey
audit
platform
enabl
facil
determin
complianc
guidelin
appropri
antimicrobi
prescrib
australian
hospit
particip
survey
collect
prescrib
data
sinc
method
data
facil
survey
submit
januari
decemb
analys
top
indic
antimicrobi
prescrib
whether
compliant
guidelin
appropri
determin
australia
nation
set
prescrib
guidelin
use
antimicrobi
prescript
assess
local
guidelin
avail
appropri
determin
use
assess
guidelin
result
antimicrobi
prescript
analys
top
indic
prescrib
antimicrobi
commun
acquir
pneumonia
prescrib
repres
total
antimicrobi
prescrib
major
compliant
guidelin
deem
inappropri
indic
highest
proport
complianc
guidelin
oraloesophag
candidiasi
follow
aspir
pneumonia
indic
highest
proport
inappropri
prescrib
infect
exacerb
chronic
obstruct
pulmonari
diseas
follow
trauma
gram
posit
anaerob
n
fungi
n
primari
therapi
use
antibiot
drainag
underw
surgeri
treat
antibiot
initi
antimicrobi
agent
within
day
carbapenem
frequent
use
n
follow
betalactamas
inhibitor
combin
penicillin
n
mortal
n
median
length
hospit
stay
day
median
durat
intraven
antibiot
day
high
cci
score
significantli
associ
poor
mortal
p
signific
advantag
carbapenem
compar
antibiot
regard
outcom
empyema
incid
side
effect
relat
antibiot
liver
dysfunct
commonli
seen
n
frequenc
escal
antibiot
significantli
decreas
p
empyema
patient
administ
appropri
dose
antibiot
n
side
effect
increas
patient
conclus
carbapenem
advantag
treatment
empyema
regard
outcom
evalu
appropri
dosag
antibiot
may
reduc
unnecessari
escal
antibiot
treat
empyema
patient
os
impact
antimicrobi
stewardship
ward
round
cardiovascular
surgic
intens
care
unit
lingju
huang
fuder
wang
jo
ku
tungi
li
yujiun
chan
yuehch
chou
chinghung
chen
background
japanes
govern
establish
nation
action
plan
antimicrobi
resist
amr
plan
aim
reduc
drugresist
microorgan
specif
antimicrobi
main
purpos
amr
plan
reduct
third
gener
oral
cephalosporin
fluoroquinolon
fq
compar
start
face
face
confer
surgic
prophylaxi
appropri
depart
sinc
thu
evalu
effect
intervent
reduct
antimicrobi
method
evalu
total
amount
oral
fq
nagoya
univers
hospit
sinc
total
amount
inhospit
outpati
total
prescript
year
extract
pharmaceut
depart
system
result
tabl
recogn
challeng
face
prescrib
antibiot
stewardship
program
asp
develop
best
practic
advisori
bpa
base
institut
broadspectrum
antibiot
polici
intern
clinic
practic
guidelin
incorpor
within
electron
medic
record
system
bpa
consist
set
indic
broadspectrum
antibiot
make
inform
access
prescrib
bpa
system
promot
appropri
antibiot
util
util
inform
bpa
asp
audit
find
seek
evalu
prescrib
knowledg
indic
antibiot
prescrib
method
prescrib
order
broadspectrum
antibiot
bpa
display
list
indic
appear
would
select
indic
complet
order
indic
select
prescrib
appropri
assess
asp
compar
signific
proport
calcul
hypergeometr
probabl
zscore
appropri
result
cours
antibiot
audit
prescrib
select
indic
order
allergi
intoler
antibiot
select
prescrib
order
discord
assess
done
asp
hypergeometr
p
x
clinic
failur
narrowspectrum
antibiot
select
cours
zscore
p
ci
cours
start
empir
understand
resist
mechan
risk
resist
dissemin
prevent
control
dapr
aureu
dapr
strain
gener
vitro
biolog
adapt
studi
method
three
dap
suscept
aureu
strain
mrsa
mrsa
mssa
isol
patient
bloodstream
infect
serial
passag
mh
broth
gradient
dap
concentr
select
resist
mutant
investig
antimicrobi
suscept
profil
growth
kinet
fit
measur
serum
toler
phenotyp
wildtyp
mutant
strain
differ
genom
background
wildtyp
mutant
also
analyz
use
whole
genom
sequenc
result
highli
dapr
mutant
obtain
screen
passag
dap
mic
increas
parent
strain
mutant
remain
toler
dap
gener
growth
three
mutant
strain
slower
parent
strain
competit
index
respect
compar
parent
strain
vitro
serum
toler
mutant
significantli
decreas
trend
also
observ
lethal
pathogen
mice
p
transmiss
electron
microscopi
flow
cytometri
demonstr
cell
wall
mutant
markedli
thicker
parent
cell
vs
furthermor
strike
decreas
cell
membran
potenti
found
one
mutant
increas
two
respect
compar
parent
strain
mutat
mprf
walk
gra
found
mutant
dapr
mutant
stabli
maintain
adapt
fit
cost
studi
indic
potenti
becom
widespread
moreov
seri
gene
mutat
may
play
role
dapr
enhanc
awar
background
clostridium
difficil
infect
cdi
reach
epidem
state
mani
develop
countri
high
incid
sever
diseas
tradit
healthcar
set
also
commun
binari
toxin
posit
epidem
strain
pcr
ribotyp
rt
caus
mani
outbreak
remain
preval
north
america
strain
never
establish
australia
howev
recent
report
increas
frequenc
cdi
due
strain
produc
binari
toxin
one
strain
increas
preval
australiawid
herein
phenotyp
characteris
strain
isol
australia
high
resolut
compar
genom
use
ascertain
evolutionari
histori
like
geograph
origin
lineag
method
c
difficil
strain
australia
n
isol
toxigen
cultur
american
strain
n
suppli
techlab
inc
genet
characteris
perform
use
techniqu
includ
toxin
gene
profil
whole
genom
sequenc
wg
silico
multilocu
sequenc
type
mlst
core
genom
singl
nucleotid
variant
snv
analys
antimicrobi
resist
determin
use
agar
incorpor
method
n
vitro
toxin
product
confirm
vero
cell
cytotox
assay
n
pathogen
observ
murin
model
n
select
isol
result
wg
mlst
cluster
evolutionari
clade
clade
core
genom
analys
reveal
group
clinic
strain
australia
n
highli
clonal
separ
snv
notabl
strain
also
share
recent
evolutionari
histori
snv
mani
indistinguish
snv
anoth
cluster
australian
strain
n
isol
decemb
juli
remark
australian
strain
share
common
ancestor
strain
virginia
usa
isol
snv
indic
lineag
north
american
origin
isol
suscept
metronidazol
vancomycin
one
show
clindamycin
erythromycin
resist
mic
mgl
mgl
respect
background
tuberculosi
tb
incid
osaka
citi
high
homeless
peopl
higher
risk
due
malnutrit
poor
live
condit
osaka
citi
promot
prioriti
measur
tb
control
free
tb
examin
public
nevertheless
still
homeless
peopl
undergo
tb
examin
studi
aim
explor
knowledg
attitud
behavior
toward
tb
examin
among
variou
group
homeless
peopl
osaka
citi
japan
identifi
barrier
facilit
tb
examin
among
method
exploratori
qualit
studi
use
indepth
interview
idi
guid
semistructur
questionnair
studi
conduct
julynovemb
target
current
previou
homeless
peopl
age
osaka
citi
recruit
carri
purpos
sampl
theoret
sampl
snowbal
sampl
use
themat
analysi
investig
triangul
data
analysi
result
conduct
idi
among
current
homeless
peopl
tb
examin
within
past
year
code
within
categori
emerg
barrier
undertak
tb
examin
due
live
highest
prioriti
surviv
feel
guilti
demotiv
health
seek
lack
inform
due
social
isol
uncertain
inform
homeless
peopl
lack
knowledg
low
risk
percept
poor
tb
examin
access
facilit
undertak
tb
examin
includ
adapt
homeless
life
inform
network
access
use
homeless
support
servic
oblig
take
tb
examin
correct
knowledg
high
risk
percept
may
reinforc
intent
continu
tb
examin
experi
free
userfriendli
tb
examin
conclus
expand
incorpor
tb
examin
variou
homeless
support
servic
educ
intervent
tb
examin
may
effect
measur
addit
improv
tb
examin
access
provis
inform
isol
homeless
peopl
base
current
homeless
support
servic
recommend
background
colistin
consid
last
resort
treat
carbapenemresist
enterobacteriacea
infect
increas
resist
global
concern
plasmid
mediat
colistin
resist
gene
found
distinct
bacteri
speci
human
anim
environ
furthermor
report
sever
animalorigin
isol
method
sampl
collect
swine
farm
cattl
farm
broiler
farm
four
provinc
jilin
shandong
henan
guangzhou
china
septemb
isol
investig
antimicrobi
suscept
test
polymeras
chain
reaction
resist
gene
screen
bla
ndm
bla
kpc
bla
imp
southern
blot
hybrid
use
determin
plasmid
locat
resist
gene
also
perform
conjug
assay
test
transfer
bla
ndm
bear
plasmid
assess
biolog
cost
plasmid
carriag
growth
curv
assay
coli
also
demonstr
resist
polymyxin
b
bla
ndm
coexist
resist
gene
locat
plasmid
size
rang
locat
plasmid
roughli
mainli
type
carbapenemas
bla
locat
nontyp
plasmid
growth
curv
transconjug
carri
orand
bla
show
advantag
fit
recipi
conclus
widespread
e
coli
k
pneumonia
isol
farm
china
resist
rate
antimicrobi
especi
polymyxin
carbapenem
show
extrem
higher
one
area
indic
antimicrobi
resist
bacteria
spread
infect
individu
whole
farm
coexist
bla
identifi
variou
sequenc
type
e
coli
low
fit
cost
suggest
urgent
need
enhanc
clinic
infect
control
decreas
dissemin
result
see
tabl
intracellular
infect
static
effect
obtain
extracellular
concentr
close
ciprofloxacin
time
higher
meropenem
amikacin
mic
ciprofloxacin
effect
drug
higher
reduct
intracellular
inoculum
biofilm
ciprofloxacin
less
potent
reduct
viabil
mic
bare
effect
higher
reduct
fluoresc
signal
drug
model
erad
bacteria
incomplet
conclus
global
antibiot
unabl
erad
infect
model
poor
bacteri
respons
may
contribut
explain
therapeut
failur
recurr
infect
vitro
activ
cefiderocol
object
studi
aim
investig
vitro
activ
cefiderocol
ceftazidimeavibactam
ceftolozanetazobactam
compar
drug
pseudomona
aeruginosa
acinetobact
baumannii
stenotrophomona
maltophilia
isol
associ
bloodstream
infect
method
total
isol
p
aeruginosa
n
baumannii
n
maltophilia
n
collect
patient
bacteraemia
evalu
minimum
inhibitori
concentr
mic
isol
antimicrobi
agent
determin
broth
microdilut
method
result
baumannii
p
aeruginosa
isol
suscept
meropenem
mic
mgl
rang
cefiderocol
ceftazidimeavibactam
ceftolozanetazobactam
respect
p
aeruginosa
respect
baumannii
respect
maltophilia
mic
mgl
cefiderocol
ceftazidimeavibactam
ceftolozanetazobactam
tigecyclin
colistin
respect
p
aeruginosa
respect
baumannii
respect
maltophilia
conclus
cefiderocol
exhibit
activ
vitro
activ
ceftazidimeavibactam
ceftolozanetazobactam
tigecyclin
colistin
maltophilia
p
aeruginosa
isol
cefiderocol
show
equival
activ
ceftazidimeavibactam
ceftolozanetazobactam
meropenemresist
baumannii
isol
background
oral
candidiasi
independ
prognost
factor
determin
progress
hiv
infect
widespread
repeat
use
azol
drug
implic
reason
emerg
fluconazol
resist
candida
strain
compound
ethoxyl
version
quaternari
ammonium
silan
variou
antimicrobi
properti
exhibit
toxic
human
cell
studi
aim
evalu
possibl
antifung
agent
fluconazoleresist
candida
strain
method
vitro
studi
conduct
test
compound
fluconazoleresist
oral
candida
isol
collect
hiv
patient
includ
c
albican
n
c
glabrata
n
c
krusei
n
c
dubliniensi
n
antifung
suscept
test
done
broth
microdilut
assay
well
microtitr
plate
contain
rpmi
media
compound
concentr
use
studi
rang
plate
incub
hour
mic
valu
read
use
spectrophotomet
nm
background
neisseria
gonorrhoea
ng
princip
pathogen
patient
male
urethr
guidelin
recommend
ceftriaxon
firstlin
treatment
regimen
gonococc
urethr
current
antimicrobi
resist
ng
problem
fluoroquinolon
also
cephalosporin
worldwid
thu
abl
use
limit
number
antimicrobi
agent
date
report
tabl
abstract
os
mic
frpm
mepm
posit
coloni
none
neg
coloni
antimicrobi
suscept
ng
carbapenem
none
faropenem
therefor
tri
evalu
method
use
strain
ng
obtain
patient
male
urethr
surveil
japan
accord
guidelin
clsi
evalu
minim
inhibitori
concentr
mic
frpm
mepm
ng
agar
plate
dilut
method
without
cystein
result
mic
frpm
rang
mic
less
ml
mepm
less
ml
mic
less
conclus
breakpoint
frpm
mepm
ng
defin
cefpodoxim
cefixim
ceftriaxon
respect
mic
frpm
slightli
high
mepm
rel
low
treatment
ng
need
use
altern
regimen
current
situat
look
potenti
therapeut
agent
os
populationbas
cohort
studi
drug
specif
effect
statin
sepsi
outcom
mengts
gabriel
lee
tzuchun
hsu
lorenzo
porta
shyshin
chang
chiahung
yo
kuangchau
tsai
matthew
lee
chienchang
lee
background
whether
statin
treatment
prove
recent
experiment
studi
antimicrobi
activ
exert
drug
class
specif
effect
sepsi
remain
unknown
method
shortterm
mortal
sepsi
patient
analyz
use
data
nation
health
insur
research
databas
use
statin
defin
cumul
use
specif
statin
atorvastatin
simvastatin
rosuvastatin
day
prior
index
sepsi
admiss
determin
associ
statin
sepsi
outcom
multivariateadjust
cox
model
propens
score
ps
match
analysi
use
background
penicillinaseresist
penicillin
cloxacillin
oxacillin
nafcillin
firstlin
therapi
methicillinsuscept
staphylococcu
aureu
mssa
infect
howev
antibiot
avail
japan
commerci
reason
situat
creat
challeng
term
select
deescal
antibiot
treat
patient
sever
mssa
infect
eg
infect
arthriti
infect
endocard
hospit
mssa
case
sensit
ampicillin
usual
select
ampicillin
confirm
neg
result
test
report
two
case
ampicillin
success
use
treat
sever
mssa
infect
case
patient
woman
whose
chief
complaint
fever
right
buttock
pain
blood
cultur
test
disclos
mssa
sensit
ampicillin
hip
joint
mri
reveal
inflammatori
chang
right
hip
joint
suggest
septic
arthriti
iliosacr
joint
examin
neg
chang
antibiot
ampicillin
sulbactam
vancomycin
ampicillin
alon
deescal
treatment
cours
unev
week
switch
ampicillin
oral
amoxicillin
discharg
case
patient
woman
whose
chief
complaint
fever
petechi
hemorrhag
observ
right
palpebr
conjunctiva
roth
spot
present
fundu
eye
pansystol
murmur
levin
iiivi
apex
note
blood
cultur
test
disclos
mssa
sensit
ampicillin
echocardiogram
reveal
veget
mm
diamet
center
posterior
leaflet
mitral
valv
infect
endocard
diagnos
infecti
brain
aneurysm
left
cerebellum
suspect
mri
examin
neg
chang
antibiot
cefazolin
ampicillin
deescal
consid
possibl
ampicillin
transit
central
nervou
system
treatment
unev
thu
far
conclus
case
mssa
sensit
ampicillin
penicillinaseresist
penicillin
unavail
ampicillin
may
becom
treatment
option
neg
test
result
confirm
vitro
synergist
activ
rifabutin
clarithromycin
imipenemcilastin
tigecyclin
mycobacterium
abscessu
complex
aristin
cheng
yitzu
tsai
chien
jungyien
poren
hsueh
wanghuei
sheng
yeechun
chen
shanchwen
chang
nation
taiwan
univers
hospit
nation
taiwan
univers
colleg
medicin
taipei
taiwan
background
mycobacterium
abscessu
intrins
multidrugresist
pathogen
emerg
global
threat
among
lipotourist
chronic
lung
diseas
autointerferon
gamma
antibodi
produc
patient
recent
studi
shown
surprisingli
rifabutin
contrast
rifampin
activ
abscessu
complex
vitro
especi
clarithromycin
resist
strain
may
consid
treatment
abscessu
diseas
explor
synergi
activ
avail
drug
ration
given
lack
new
activ
drug
method
test
vitro
synergi
rifabutin
antimicrobi
often
use
combinatori
therapi
rapidli
grow
mycobacteria
refer
clinic
isol
molecularli
identifi
subspeci
abscessu
complex
use
checkerboard
method
abscessu
subsp
massiliens
isol
rifabutin
tigecyclin
abscessu
subsp
massiliens
isol
fraction
inhibitori
concentr
combin
rifabutin
amoxicillinclavulan
acid
doxycyclin
moxifloxacin
clofazimin
neither
synergist
addit
wherea
combin
rifabutin
amikacin
linezolid
cefoxitin
ceftibutem
synergist
abscessu
subsp
massiliens
isol
rifabutin
base
combin
demonstr
antagon
conclus
safeti
toler
ad
rifabutin
standard
clarithromycin
imipenemcilastin
tigecyclinecontain
regimen
test
clinic
trial
result
suscept
test
rifabutin
combin
merit
clinic
valid
treat
abscessu
diseas
os
capsular
serotyp
polysaccharid
product
hypervirul
k
pneumonia
strain
bacteremia
japan
michinobu
yoshimura
atsushi
togawa
background
hypervirul
hv
k
pneumonia
strain
associ
invas
syndrom
liver
abscess
assess
effect
capsular
serotyp
induct
hv
mucoid
phenotyp
effect
phenotyp
product
capsular
lipo
polysaccharid
method
retrospect
studi
k
pneumonia
bacteremia
case
conduct
tertiarycar
univers
hospit
japan
string
test
perform
isol
find
hv
strain
mucoid
phenotyp
determin
visual
inspect
coloni
express
capsular
serotyp
magarmpa
gene
determin
pcr
clinic
manifest
collect
medic
record
result
total
patient
k
pneumonia
bacteremia
identifi
studi
period
isol
determin
hv
strain
serotyp
predomin
strain
p
serotyp
strain
hv
mucoid
phenotyp
observ
often
strain
p
howev
logist
regress
analysi
mucoid
phenotyp
independ
associ
serotyp
odd
ratio
confid
interv
maga
rmpa
gene
express
strongli
associ
serotyp
p
hv
mucoid
phenotyp
associ
overproduct
capsular
polysaccharid
figur
liver
abscess
format
strongli
associ
mucoid
phenotyp
odd
ratio
confid
interv
hv
phenotyp
serotyp
associ
either
bacteri
phenotyp
liver
abscess
format
conclus
serotyp
signific
virul
factor
invas
syndrom
induct
mucoid
phenotyp
overproduct
capsular
polysaccharid
k
pneumonia
bloodstream
infect
background
natur
histori
studi
hiv
infect
pregnanc
show
prior
antiretrovir
therapi
infant
born
hivinfect
mother
becom
infect
hiv
inutero
infect
macrophag
tropic
viral
strain
viru
commonli
vertic
transmit
strain
evid
strong
specif
tcell
respons
cord
peripher
blood
exposeduninfect
neonat
howev
exact
mechan
prevent
mothertofoetu
transmiss
mft
particular
role
macrophag
remain
unknown
aim
studi
determin
whether
placent
macrophag
affect
highli
activ
antiretrovir
therapi
haart
administ
hiv
posit
women
pregnanc
method
placenta
seven
hivinfect
women
receiv
haartand
noninfect
women
obtain
within
two
hour
deliveri
fix
formalin
embed
paraffin
repres
tissu
section
cut
repres
area
placenta
includ
matern
surfac
chorion
plate
character
placent
cell
macrophag
phenotyp
tissu
section
stain
panmacrophag
antibodi
marker
cell
figur
section
intestin
patient
crohn
diseas
includ
posit
control
sampl
exhibit
larg
number
strongli
posit
cell
code
placent
slide
evalu
histolopathologist
experienc
placent
patholog
pb
without
knowledg
patient
hiv
statu
transmiss
outcom
result
compar
healthi
hivneg
control
foetal
capillari
test
case
show
significantli
reduc
number
cell
mean
sd
respect
p
figur
differ
numer
densiti
macrophagemonocyt
within
villou
stroma
trophoblast
matern
vascular
compart
two
group
conclus
reduc
frequenc
macrophag
foetal
capillari
haart
expos
placenta
suggest
region
differ
local
placent
immun
select
foetal
immun
escap
may
provid
protect
mechan
inutero
hiv
transmiss
background
antibiot
resist
mount
challeng
modern
era
holist
treatment
modal
could
serv
solut
ultrahigh
dilut
homeopath
medicin
select
basi
symptom
similar
act
favor
mani
infecti
condit
clinic
set
pilot
studi
attempt
studi
action
commonli
prescrib
homeopath
medicin
directli
cultur
mrsa
isol
concurr
test
effici
medicin
diseas
individu
method
mrsa
posit
isol
differ
clinic
sampl
isol
use
blood
cultur
method
homeopath
medicin
commonli
prescrib
variou
infect
select
sensit
disc
medicin
prepar
follow
gmp
standard
homoeopath
dilut
appli
mm
diamet
steril
whatman
filter
paper
allow
dri
complet
sampl
infect
cultur
bacteri
strain
identifi
individu
steril
condit
homeopath
sensit
disc
fix
bacteri
cultur
plate
visibl
zone
inhibit
measur
around
disc
incub
hr
result
cultur
result
show
gram
posit
mrsa
isol
homeopath
remedi
show
zone
inhibit
around
sensit
disc
multipl
sensit
drug
isol
conclus
pilot
studi
suggest
homeopath
medicin
act
invitro
well
invivo
condit
warrant
studi
background
toxigen
strain
clostridium
difficil
caus
diseas
product
larg
clostridi
toxin
andor
b
nontoxigen
c
difficil
ntcd
strain
produc
either
toxin
thu
consid
clinic
irrelev
howev
strain
c
difficil
includ
ntcd
produc
adpribosyl
toxin
cdt
signific
unknown
strain
recent
isol
patient
sever
diarrhoea
suggest
possibl
symptomat
infect
due
cdtntcd
howev
limit
studi
investig
function
cdt
role
c
difficil
infect
sought
investig
differ
virul
trait
toxigen
cdtntcd
c
difficil
strain
known
preval
anim
human
method
molecular
type
experi
use
three
method
pcr
ribotypingpcrrt
multilocu
sequenc
typingmlst
pulsedfield
gel
electrophoresispfg
perform
divers
collect
cdtntcd
strain
human
n
bovin
n
porcin
n
food
n
environ
n
identifi
best
approach
type
strain
phenotyp
experi
perform
includ
germin
sporul
assay
motil
test
cell
cytotox
assay
assess
pathogen
murin
model
infect
subset
cdtntcd
strain
underw
whole
genom
sequenc
identifi
genet
element
associ
surviv
pathogen
result
divers
cdtntcd
strain
best
illustr
pfge
reveal
three
discret
pulsotyp
within
one
ribotyp
howev
method
labor
intens
irreproduc
isol
belong
mlst
clade
characterist
share
hypervirul
c
difficil
lineag
motil
studi
show
cdtntcd
strain
phenotyp
nonmotil
delet
glycosyl
gene
earlystag
flagellar
gene
region
flagellar
operon
seven
ribotyp
slightli
motil
significantli
less
refer
strain
lack
three
glycosyltransferas
gene
essenti
c
difficil
flagellum
assembl
full
motil
flagellin
flagella
cap
gene
flic
flid
involv
adher
host
colonis
conserv
strain
includ
refer
strain
genet
variat
cell
surfac
protein
slpa
also
note
across
differ
ribotyp
confirm
toxic
cdtntcd
c
difficil
strain
vero
cell
howev
demonstr
mous
model
diseas
mice
infect
cdtntcd
strain
surviv
infect
despit
detect
high
number
spore
cfug
faec
either
postinfect
show
sign
diarrhoea
except
mice
infect
soft
faecesdiarrhoea
hour
postinfect
weight
loss
possibl
mous
model
adequ
demonstr
diseas
due
cdtntcd
c
difficil
strain
conclus
studi
provid
first
indepth
analysi
cdtntcd
c
difficil
strain
contribut
current
limit
knowledg
strain
potenti
role
c
difficil
diseas
os
pathogen
role
stringent
respons
oxid
stress
respons
biofilm
format
helicobact
pylori
shigeru
kamiya
hideo
yonezawa
takako
osaki
tomoko
hanawa
depart
infecti
diseas
kyorin
univers
school
medicin
mitaka
tokyo
japan
background
report
stringent
respons
global
bacteri
respons
nutrit
limit
mediat
accumul
cellular
p
ppgpp
guanosin
tetraand
pentaphosph
p
ppgpp
synthes
rela
andor
spot
hydrolyz
spot
bifunct
enzym
case
h
pylori
spot
enzym
involv
synthesi
hydrolysi
p
ppgpp
method
present
studi
spot
isogen
mutant
h
pylori
strain
tk
gener
fragment
contain
spot
cat
allel
construct
pcr
overlap
extens
use
disrupt
target
gene
homolog
recombin
result
signific
differ
growth
rate
nutrient
rich
condit
mutant
parent
strain
oxid
stress
respons
mutant
parent
strain
evalu
although
signific
differ
sensit
hydrogen
peroxid
parent
strain
strain
much
sensit
activ
oxygen
parent
strain
biofilm
form
abil
parent
strain
evalu
convent
crystal
violet
procedur
biofilm
format
stain
particularli
strain
significantli
decreas
compar
parent
strain
conclus
result
impli
stringent
respons
involv
pathogenesi
h
pylori
infect
chimer
virul
antimicrobialresist
plasmid
salmonella
enterica
serovar
choleraesui
chyiliang
chen
rajendra
prasad
janapatla
chenghsun
chiu
background
zoonot
salmonella
enterica
serovar
choleraesui
choleraesui
caus
paratyphoid
pig
well
bacteremia
mycot
aneurysm
human
may
carri
virul
plasmid
sometim
antimicrobialresist
plasmid
aim
studi
deciph
like
mechan
virulenceresist
chimera
plasmid
form
choleraesui
method
whole
plasmid
sequenc
choleraesui
strain
determin
use
shotgun
clone
sequenc
sequenc
annot
comparison
perform
determin
sequenc
respons
format
chimer
virulenceresist
chimer
plasmid
clinic
choleraesui
isol
also
examin
result
sequenc
long
identifi
chimera
virul
multidrugresist
found
choleraesui
strain
contain
variou
mobil
dna
includ
prophag
insert
sequenc
integron
transposon
especi
complex
transposon
dissect
junction
site
chimera
defect
sequenc
integras
gene
int
attach
site
att
found
like
result
stabl
chimera
plasmid
due
failur
excis
chimera
similar
structur
chimera
also
found
larg
plasmid
choleraesui
conclus
delet
int
att
sti
appear
block
chimera
excis
thu
gener
irrevers
stabl
chimera
genet
variat
virul
antimicrobialresist
plasmid
pose
health
risk
gener
public
os
solithromycin
inhibit
product
induc
streptococcu
pneumonia
haemophilu
influenza
human
airway
epitheli
cell
kenji
ota
norihito
kaku
kosuk
kosai
naoki
uno
hiroo
hasegawa
taiga
miyazaki
koichi
izumikawa
hiroshi
muka
katsunori
yanagihara
depart
laboratori
medicin
nagasaki
univers
graduat
school
biomed
scienc
nagasaki
japan
depart
respiratori
medicin
nagasaki
univers
graduat
school
biomed
scienc
nagasaki
japan
depart
infecti
diseas
nagasaki
univers
graduat
school
biomed
scienc
nagasaki
japan
background
solithromycin
sol
novel
macrolid
broad
spectrum
potent
antiinflammatori
effect
might
benefici
treatment
communityacquir
bacteri
pneumonia
previou
studi
elucid
macrolid
inhibit
overexpress
immunomodulatori
effect
purpos
studi
reveal
antiinflammatori
effect
sol
inhibit
bacteriainduc
overproduct
method
use
streptococcu
pneumonia
sp
lysat
haemophilu
influenza
hi
lysat
induc
hypersecret
cell
cultur
liquid
medium
grown
incub
overnight
serum
starvat
cell
stimul
variou
concentr
lysat
hour
inhibit
studi
cell
treat
sol
simultan
stimul
studi
protein
level
measur
enzymelink
immunosorb
assay
elisa
result
cell
stimul
sp
hi
lysat
respect
cell
sp
lysat
induc
product
significantli
p
hi
p
cell
sp
p
hi
p
inhibit
studi
figur
sol
inhibit
product
cell
induc
sp
hi
significantli
concentr
versu
p
versu
p
respect
similarli
sol
inhibit
product
cell
induc
sp
hi
significantli
concentr
versu
p
versu
p
respect
conclus
sol
show
antiinflammatori
effect
inhibit
product
induc
sp
hi
cell
first
studi
reveal
immunomodulatori
effect
sol
human
airway
epitheli
cell
use
bacteri
stimul
prophylaxi
colorect
surgeri
howev
littl
known
longterm
effect
oral
antibiot
bacteri
flora
surgic
ward
nov
dec
perform
random
control
trial
verifi
efficaci
oral
antibiot
prophylaxi
patient
undergo
colorect
surgeri
jmto
prev
trial
conclud
oral
antibiot
prophylaxi
reduc
risk
ssi
depend
result
use
oral
antibiot
prophylaxi
kanamycin
metronidazol
patient
undergo
colorect
surgeri
except
patient
contraind
studi
investig
effect
oral
antibiot
use
year
bacteri
flora
surgic
ward
method
retrospect
collect
report
cultureposit
specimen
submit
surgic
ward
jan
dec
frequenc
trend
bacteria
examin
result
total
organ
identifi
top
seven
isol
organ
e
coli
klebsiella
pneumonia
enterococcu
faecali
pseudomona
aeruginosa
enterobact
cloaca
staphylococcu
aureu
enterococcu
faecium
six
speci
except
e
faecium
consist
seven
major
speci
bacteria
report
nation
surveil
studi
japan
result
seem
oral
antibiot
prophylaxi
affect
bacteri
flora
isol
surgic
ward
annual
trend
proport
isol
organ
follow
e
coli
k
pneumonia
e
faecali
p
aeruginosa
e
cloaca
aureu
data
show
signific
chang
specif
organ
five
year
conclus
oral
antibiot
prophylaxi
use
year
may
affect
bacteri
flora
surgic
ward
background
cancer
patient
often
admit
intens
care
unit
icu
due
vulner
health
condit
suscept
colon
infect
studi
aim
address
longterm
impact
posit
cultur
result
admiss
oneyear
mortal
among
cancer
patient
admit
icu
method
conduct
retrospect
cohort
studi
taichung
veteran
gener
hospit
vghtc
adult
patient
histori
cancer
least
one
icu
admiss
vghtc
cancer
diagnosi
includ
includ
first
icu
admiss
follow
cancer
diagnosi
index
icu
admiss
data
regard
cancer
diagnosi
locat
treatment
retriev
cancer
registri
data
demograph
inform
icu
admiss
diagnos
cultur
result
medic
pull
electron
medic
record
exposur
posit
cultur
result
index
admiss
outcom
mortal
within
one
year
index
icu
admiss
assess
kaplanmei
surviv
curv
compar
mortal
patient
posit
cultur
result
patient
without
posit
cultur
result
use
logrank
test
use
multivari
cox
proport
hazard
regress
model
adjust
confound
evalu
influenc
posit
cultur
result
oneyear
mortal
result
includ
cancer
patient
least
one
icu
admiss
follow
cancer
diagnos
figur
abstract
os
posit
cultur
result
admiss
die
within
one
year
icu
admiss
compar
patient
surviv
within
one
year
icu
admiss
patient
die
significantli
like
posit
cultur
result
vs
higher
apacheii
score
median
vs
receiv
mechan
ventil
vs
receiv
renal
replac
vs
kaplanmei
surviv
analysi
indic
posit
cultur
blood
respiratori
urin
associ
significantli
increas
oneyear
mortal
logrank
test
p
figur
posit
cultur
skin
soft
tissu
abdomen
impact
multivari
cox
proport
hazard
regress
analysi
show
posit
cultur
blood
respiratori
urin
adjust
hazard
ratio
confid
interv
significantli
associ
increas
hazard
death
within
one
year
icu
admiss
adjust
factor
conclus
posit
cultur
result
icu
admiss
may
associ
poor
longterm
surviv
among
critic
ill
cancer
patient
os
strict
glycem
control
prevent
surgic
site
infect
gastroenterolog
surgeri
patient
without
diabet
mellitu
toshi
tsuchida
yoshio
takesu
kaoru
ichiki
kazuhiko
nakajima
takashi
ueda
motoi
uchino
hiroki
ikeuchi
background
periop
hyperglycemia
risk
factor
surgic
site
infect
ssi
metaanalysi
confirm
benefit
intens
protocol
target
mgdl
reduc
ssi
aim
studi
evalu
benefit
strict
glycem
control
reduc
ssi
gastroenterolog
surgeri
patient
without
diabet
mellitu
dm
method
patient
underw
esophagectomi
gastrectomi
colon
rectal
surgeri
hepatobiliarypancreat
surgeri
hyogo
colleg
medicin
enter
studi
highest
blood
glucos
level
bg
within
hour
gastroenterolog
surgeri
evalu
result
total
patient
analyz
patient
dm
incid
bg
mgdl
dm
patient
nondm
patient
mgdl
dm
nondm
respect
ssi
rate
significantli
higher
dm
patient
compar
nondm
patient
vs
p
unexpectedli
hyperglycemia
signific
risk
factor
ssi
among
dm
patient
ci
p
mgdl
ci
p
mgdl
contrast
nondm
patient
bg
mgdl
found
increas
odd
ssi
ci
p
mgdl
ci
p
mgdl
addit
significantli
increas
risk
ssi
demonstr
patient
mgdl
mgdl
compar
refer
group
mgdl
nondm
patient
conclus
target
bg
mgdl
recommend
patient
without
dm
undergo
gastroenterolog
surgeri
addit
studi
requir
determin
optim
target
blood
glucos
level
dm
patient
limit
studi
singl
maxim
postop
elev
bg
evalu
correct
bg
insulin
therapi
taken
account
background
antibacteri
linen
studi
use
wide
mani
hospit
world
yet
use
vietnam
mani
hospit
vietnam
challeng
high
incid
hospit
acquir
infect
hai
studi
conduct
estim
effect
antibacteri
linen
reduc
incid
hospit
acquir
infect
method
experiment
studi
control
intervent
estim
effect
use
antibacteri
linen
name
nm
coat
antibacteri
resin
solut
studi
figur
abstract
os
oneyear
surviv
curv
patient
without
posit
blood
respiratori
urin
cultulr
restul
conduct
intens
care
unit
burn
depart
tropic
diseas
depart
two
period
interventionus
normal
linenfrom
januari
may
interventionus
antibacteri
linenfrom
june
decemb
purpos
studi
estim
compar
incid
hai
densiti
bacteria
linen
air
patient
room
two
period
result
total
patient
period
differ
regard
clinic
characterist
patient
group
period
intervent
use
antibacteri
linen
incid
hai
decreas
rate
posit
cultur
healthcar
worker
uniform
decreas
rate
posit
cultur
patient
uniform
bed
sheet
decreas
background
popul
pyramid
shift
toward
increas
elderli
popul
elderli
person
face
underli
diseas
decreas
biolog
defens
mechan
bring
need
optim
antibacteri
treatment
elderli
focus
elderli
patient
rare
ever
studi
method
elderli
patient
age
hospit
infecti
diseas
retrospect
analyz
june
may
elderli
patient
divid
two
group
one
elderli
patient
year
group
elderli
patient
year
result
infecti
focus
consist
pneumonia
urinari
tract
infect
sepsi
multipl
infect
effect
initi
antibiot
effect
elderli
elderli
number
similar
howev
overal
surviv
rate
elderli
day
elderli
elderli
display
significantli
lower
surviv
rate
p
figur
multivari
analysi
risk
factor
affect
surviv
prognosi
found
advers
prognost
risk
factor
elderli
malign
copd
initi
antibiot
effect
tabl
wherea
elderli
risk
factor
includ
perform
statu
initi
antibiot
effect
tabl
b
elderli
elderli
initi
antibiot
effect
associ
creat
better
outcom
background
campylobact
fetu
part
commens
flora
found
gastrointestin
tract
cattl
rare
caus
human
infect
c
fetusinfect
aneurysm
cfia
rare
fatal
infect
clinic
epidemiolog
risk
factor
optim
treatment
cfia
still
unclear
method
present
man
diagnos
c
fetu
bacteremia
infect
left
common
iliac
arteri
aneurysm
spondylodisc
success
treat
antibiot
surgeri
also
review
english
japanes
literatur
use
pubm
ichusi
http
wwwjamasorjp
japanes
medic
abstract
societi
cfia
episod
cfia
defin
patient
aneurysm
least
posit
blood
cultur
andor
posit
arteri
wall
specimen
cultur
yield
c
fetu
result
identifi
case
english
japanes
literatur
case
also
includ
appar
cfia
frequent
report
franc
follow
japan
median
age
patient
year
rang
year
men
patient
present
fever
abdomin
pain
diarrhea
underli
diseas
cardiovascular
diseas
hypertens
alcohol
malign
diabet
mellitu
exposur
raw
meat
antimicrobi
agent
initi
administ
follow
penicillin
miss
data
case
aminoglycosid
carbapenem
fluoroquinolon
case
median
durat
antimicrobi
therapi
day
overal
mortal
rate
howev
rate
increas
case
cfia
ruptur
regardless
type
initi
antimicrobi
agent
use
patient
undergon
surgeri
aneurysm
ruptur
favor
outcom
conclus
knowledg
largest
literatur
review
cfia
result
suggest
prompt
surgic
intervent
favor
outcom
cfia
furthermor
frequent
report
case
aneurysm
franc
japan
might
due
habitu
consumpt
raw
meat
howev
clinic
epidemiolog
investig
cfia
includ
dietari
histori
need
os
staphylococcu
argenteu
emerg
pathogen
communityonset
bacteremia
associ
high
mortal
chienyu
chi
hao
lee
shinhei
du
xiaomei
wang
taifen
lee
chunhs
liao
sheyi
chen
leejen
teng
poren
hsueh
background
enterococcu
faecali
import
pathogen
communityacquir
nosocomi
infect
worldwid
common
urinari
tract
endovascular
intraabdomin
wound
infect
e
faecali
isol
suscept
glycopeptid
commonli
use
e
faecali
bacteremia
howev
use
glycopeptid
therapi
may
lead
unnecessari
advers
effect
excess
cost
emerg
glycopeptid
resist
pathogen
limit
data
associ
choic
antimicrobi
agent
e
faecali
bacteremia
outcom
object
studi
assess
efficaci
versu
glycopeptid
therapi
e
faecali
bacteremia
method
retrospect
analysi
conduct
medic
center
taiwan
adult
patient
e
faecali
isol
blood
sampl
jan
dec
treat
appropri
antibiot
analyz
patient
classifi
glycopeptid
group
group
accord
major
therapi
defin
effect
antibiot
use
day
major
time
antibiot
cours
clinic
featur
compar
two
group
primari
outcom
mortal
cox
proport
regress
model
propens
scoreadjust
multivari
analys
use
explor
factor
associ
primari
outcom
result
total
patient
enrol
final
analysi
thirtyeight
patient
receiv
glycopeptid
therapi
patient
receiv
therapi
glycopeptid
group
icu
admiss
septic
shock
mechan
ventil
observ
frequent
patient
associ
higher
apach
ii
score
higher
mortal
observ
glycopeptid
group
background
cerebr
gumma
rare
complic
syphili
usual
present
late
stage
noninvas
diagnosi
brain
mass
lesion
difficult
resect
definit
diagnosi
experienc
human
immunodefici
viru
hiv
posit
case
cerebr
syphilit
gumma
aris
shortli
amoxicillin
therapi
method
made
oper
resect
brain
tumor
use
addit
examin
treponema
pallidum
immunohistochem
stain
use
rabbit
purifi
igg
fraction
polyclon
antibodi
pallidum
specif
pcr
target
pola
homogen
brain
specimen
done
later
pallidum
dna
analyz
subtyp
yearold
male
gener
fatigu
diagnos
syphili
also
hiv
infect
count
oral
high
dose
amoxicillin
administ
eight
week
follow
combin
antiretrovir
therapi
six
month
later
visit
emerg
room
brain
mass
lesion
right
tempor
lobe
partial
lobectomi
perform
tent
diagnosi
glioblastoma
frozen
section
later
detect
pallidum
resect
tissu
pcr
immunostain
final
diagnosi
cerebr
syphilit
gumma
caus
treponema
pallidum
strain
type
rare
subtyp
oper
patient
recov
without
complic
receiv
addit
ceftriaxon
background
environment
reservoir
import
sourc
multidrugresist
acinetobact
baumannii
mrab
outbreak
role
postoutbreak
environment
surveil
guid
sustain
control
effort
examin
method
enhanc
environment
disinfect
regular
environment
surveil
ward
commun
area
outbreak
perform
universityaffili
hospit
assess
use
environment
cultur
predict
patient
mrab
weekli
surveil
commun
area
continu
month
outbreak
intervent
ward
result
eight
patient
immedi
surround
commun
area
contamin
mrab
start
outbreak
enhanc
environment
disinfect
isol
mrab
patient
commun
area
render
cultur
neg
mrab
postoutbreak
weekli
surveil
commun
area
show
identif
newli
diagnos
mrab
patient
significantli
correl
preced
environment
contamin
mrab
p
incid
nosocomi
mrab
infect
significantli
lower
intervent
compar
nonintervent
ward
vs
per
patientday
p
mrab
isol
environment
patient
sampl
belong
mlst
posit
conclus
environment
surveil
may
serv
surrog
marker
presenc
mrab
carrier
implement
time
infect
control
measur
guid
environment
cultur
mrab
minim
risk
mrab
outbreak
two
clonal
relat
divers
k
pneumonia
e
coli
strain
carri
bla
conjug
incac
plasmid
exhibit
ident
restrict
pattern
entir
sequenc
deriv
establish
bp
long
incac
plasmid
harbour
three
resist
island
tet
stra
strb
bla
blc
suge
contain
bla
arsen
resist
operon
integron
mercuri
resist
operon
uniform
plasmid
six
isol
remain
two
isol
also
harbour
bla
integron
although
plasmid
two
isol
transfer
conclus
find
confirm
high
preval
vimproduc
enterobacteriacea
mubarak
hospit
kuwait
due
plasmid
outbreak
conjug
incac
episom
harbour
integron
also
present
remain
strain
carri
nonconjug
vim
plasmid
os
ampicillin
plu
ceftriaxon
could
treat
safe
infect
endocard
caus
enterococcu
faecali
hanako
yoshihara
takahiko
fukuchi
hitoshi
sugawara
jichi
medic
univers
saitama
medic
center
background
ampicillin
plu
gentamicin
firstlin
therapi
treat
infect
endocard
caus
enterococcu
faecali
case
renal
dysfunct
ceftriaxon
seldom
administ
instead
gentamicin
report
ampicillin
plu
ceftriaxon
effect
ampicillin
plu
gentamicin
report
case
ampicillin
plu
ceftriaxon
effect
treat
infect
endocard
caus
e
faecali
case
patient
woman
underw
aortic
valv
replac
bioprosthet
valv
year
prior
attend
hospit
stool
bloodi
thu
underw
colonoscopi
biopsi
reveal
colon
adenoma
two
week
later
felt
lower
back
pain
worsen
admit
hospit
blood
cultur
test
disclos
e
faecali
lumbar
vertebra
mri
show
high
densiti
area
level
short
tau
invers
recoveri
therefor
administ
ampicillin
pyogen
spondyl
caus
e
faecali
bacillemia
persist
diagnos
possibl
infect
endocard
accord
modifi
duke
criteria
ad
ceftriaxon
instead
gentamicin
renal
dysfunct
serum
creatinin
level
mgdl
nine
day
ad
ceftriaxon
e
faecali
final
confirm
neg
blood
cultur
therefor
continu
treatment
anoth
week
follow
infect
endocard
relaps
conclus
although
treatment
infect
endocard
caus
e
faecali
ampicillin
plu
ceftriaxon
becom
wide
known
remain
seldom
use
worldwid
case
concomit
use
effect
patient
renal
function
deterior
hope
treatment
might
adopt
broad
case
strain
multi
drug
mdr
extrem
xdr
pan
drug
resist
pdr
produc
carbapenemas
common
one
ndm
enzym
former
one
exceed
latter
one
sinc
multipl
carbapenemas
produc
total
isol
produc
ndm
oxa
type
enzym
appear
stabilis
kpc
produc
strain
encount
overal
rate
colistin
resist
first
encount
respect
reach
one
posit
isol
posit
one
detect
nonsuscept
tigecyclin
vari
studi
period
among
k
pneumonia
strain
major
pfge
cluster
repres
k
pneumonia
identifi
strain
multipl
mlst
type
repres
increas
colistin
aminoglycosid
resist
time
coincid
spread
clone
ie
strain
sinc
sinc
isol
carri
least
one
modifi
enzym
gene
former
one
mostli
arma
latter
one
exclus
rmtf
conclus
data
show
burden
cre
region
highli
complex
phenomenon
consider
affect
spread
highli
resist
clone
close
monitor
molecular
type
could
offer
chanc
understand
henc
limit
spread
cre
os
genom
wide
dissect
pneumonia
nonsuscept
wide
rang
antibiot
circul
among
preschool
children
central
vietnam
hiroshi
fujii
koya
ariyoshi
graduat
school
biomed
scienc
nagasaki
univers
nagasaki
japan
institut
tropic
medicin
nagasaki
univers
nagasaki
japan
background
previou
populationbas
studi
reveal
high
carriag
rate
pneumonia
sp
nonsuscept
wide
rang
antibiot
includ
carbapenem
spn
among
preschool
children
yr
live
central
vietnam
healthi
children
commun
hospit
children
acut
respiratori
infect
approxim
analyz
spn
sampl
relat
global
circul
resist
sp
clone
predomin
clone
pmen
pneumococc
molecular
epidemiolog
network
doubl
loci
variant
dlv
follow
well
pmen
strain
new
st
dlv
identifi
spn
object
studi
clarifi
spn
vietnam
genet
evolv
method
studi
spn
defin
mepm
mic
ml
pcg
ctx
mic
whole
genom
sequenc
wg
use
illumina
miseq
platform
perform
search
recombin
region
associ
high
antibiot
mic
creat
phylogeni
spn
put
recombin
event
analyz
use
gubbin
algorithm
result
wg
success
done
total
sp
isol
spn
n
sp
control
n
serogroupserotyp
n
n
n
n
reveal
differ
allel
respect
one
three
allel
ident
associ
high
mic
pattern
pcg
ctx
analysi
reveal
recombin
event
rare
observ
rm
ratio
probabl
due
disrupt
compet
pilu
comgc
gene
insert
prophag
wherea
frequent
recombin
seen
rm
ratio
recombin
event
span
associ
high
mic
pattern
also
indic
probabl
deriv
ancestor
recombin
event
acquir
genom
region
span
ddl
potenti
donor
background
hypervirul
klebsiella
pneumonia
major
caus
communityacquir
pyogen
infect
asian
countri
capsular
type
k
pneumonia
strain
wellknown
high
virul
associ
invas
infect
usual
suscept
antimicrobi
except
ampicillin
littl
known
regard
clinic
molecular
characterist
antimicrobialresist
k
pneumonia
strain
method
retrospect
studi
evalu
patient
infect
capsular
type
k
pneumonia
strain
taiwanes
medic
center
april
march
isol
invas
diseas
bacteremia
pneumonia
pyogen
abscess
includ
studi
antimicrobialresist
strain
defin
nonsuscept
agent
except
ampicillinamoxicillin
clinic
characterist
antimicrobialresist
k
pneumonia
infect
analyz
strain
underw
analysi
pulsefield
gel
electrophoresi
pfge
multilocu
sequenc
type
mlst
resist
mechan
vivo
virul
vivo
virul
resist
mechan
two
isogen
strain
differ
resist
phenotyp
compar
result
among
capsular
type
k
pneumonia
strain
antimicrobialresist
strain
identifi
mortal
rate
infect
caus
antimicrobialresist
strain
significantli
higher
caus
antimicrobialsensit
strain
vs
p
vs
p
respect
antimicrobialresist
strain
associ
nosocomi
n
healthcareassoci
infect
n
clonal
relat
pfge
sequenc
type
st
strain
n
n
n
half
strain
exhibit
high
vivo
virul
mous
lethal
experi
lethal
dose
cfu
major
resist
mechan
involv
presenc
overexpress
efflux
pump
acraboqxab
one
strain
exhibit
higher
resist
level
cephalosporin
compar
isogen
counterpart
due
overexpress
cephalosporinas
retain
high
vivo
virul
conclus
antimicrobialresist
capsular
type
strain
infect
associ
high
mortal
rate
virul
k
pneumonia
strain
evolv
harbor
variou
resist
mechan
may
repres
emerg
sever
threat
public
health
infecti
diseas
resist
antibiot
believ
major
public
health
concern
worldwid
effect
empir
therapi
key
factor
understand
local
antibiot
resist
epidemiolog
critic
abl
adapt
empir
therapeut
strategi
improv
diagnosi
prevent
aim
studi
identifi
current
trend
antibiot
resist
analyz
local
epidemiolog
larg
hospit
center
marseil
franc
threeyear
period
januari
decemb
data
antibiot
suscept
collect
public
laboratori
hospit
marseil
focus
top
common
bacteria
isol
period
antibiot
suscept
test
ast
perform
bacteri
speci
isol
top
frequent
bacteria
repres
ast
perform
n
overal
found
level
resist
antibiot
worri
common
bacteria
signific
decreas
resist
key
antibiot
includ
aminoglycosid
penicillin
cephalosporin
e
coli
p
mirabili
marcescen
k
oxytoca
observ
increas
resist
cephalosporin
carbapenem
k
pneumonia
p
aeruginosa
morganii
obtain
decreas
wildtyp
strain
correspond
full
suscept
panel
compos
antibiot
test
moreov
observ
low
level
resist
carbapenem
gramneg
bacteria
less
posit
blood
cultur
sampl
bacteria
top
thu
studi
demonstr
level
resist
antibiot
common
bacteria
involv
infect
beyond
recent
alarmist
public
predict
mortal
due
mdr
media
believ
epidemiolog
data
use
implement
therapeut
strategi
continu
realtim
surveil
evolut
resist
antibiot
common
bacteria
patient
decolon
rifampin
usag
two
patient
mssa
colon
enrol
show
evid
recolon
geneticallyunrel
mssa
strain
two
month
discontinu
treatment
five
rifr
strain
two
patient
isol
rifampin
exposur
sequenc
rpob
gene
rifr
aureu
isol
reveal
differ
mutat
site
mssa
mrsa
isol
conclus
rifr
aureu
nasal
carriag
isol
patient
receiv
rifampincontain
regimen
might
acquir
resist
extrins
sourc
rather
develop
mechan
rifampin
exposur
background
etiolog
infect
central
nervou
system
cn
nepal
often
goe
unrecogn
due
underdevelop
laboratori
facil
might
lead
overtreat
broadspectrum
antibiot
possibl
side
effect
addit
use
counter
antibiot
arriv
hospit
widespread
area
complic
diagnost
evalu
clinician
aim
studi
investig
microbi
etiolog
cn
infect
hospit
nepal
method
novemb
februari
cerebrospin
fluid
csf
collect
consecut
patient
present
unit
mission
hospit
tansen
nepal
symptom
possibl
cn
infect
patient
data
regist
analysi
blood
cell
csf
includ
differenti
count
perform
hospit
sampl
initi
store
transport
dri
ice
sweden
multiplex
pcr
perform
target
six
bacteria
seven
virus
two
fungi
filmarray
panel
biofir
biomerieux
result
patient
csf
white
cell
count
suggest
cn
infect
bacteria
analyz
assay
h
influenza
found
sampl
pneumonia
n
meningitidi
sampl
sampl
posit
h
influenza
pneumonia
neither
l
monocytogen
e
coli
agalactia
found
cryptococcu
neoforman
gatti
found
four
sampl
virus
detect
includ
enteroviru
n
varicella
zoster
viru
n
herp
simplex
viru
n
human
herp
viru
n
sampl
neg
patient
taken
antibiot
lumbar
punctur
mainli
oral
cephalosporin
conclus
use
filmarray
multiplex
pcr
panel
detect
import
pathogen
known
caus
cn
infect
rel
larg
proport
sampl
posit
h
influenza
pneumonia
unexpect
preval
dna
bacteria
could
case
confirm
method
consid
clinic
relev
rel
larg
proport
sampl
test
neg
pathogen
includ
pcr
assay
indic
cn
infect
area
often
caus
import
pathogen
virus
mycobacteria
interestingli
major
patient
taken
broadspectrum
antibiot
arriv
hospit
highlight
urgent
need
improv
routin
diagnost
background
numer
studi
indic
appropri
empir
antibiot
therapi
associ
surviv
adult
patient
bloodstream
infect
howev
util
empir
antibiot
therapi
pediatr
patient
bloodstream
infect
yet
well
studi
purpos
studi
investig
impact
inappropri
empir
antibiot
therapi
mortal
pediatr
patient
bloodstream
infect
method
retrospect
collect
data
pediatr
patient
age
year
posit
blood
cultur
univers
hospit
associ
use
inappropri
empir
therapi
mortal
investig
inappropri
empir
antibiot
therapi
defin
use
antibiot
within
hour
blood
cultur
sucept
vitro
bacteria
detect
blood
cultur
result
total
event
bacteremia
pediatr
patient
analyz
event
hospit
acquir
infect
pediatr
patient
die
within
day
event
due
gramposit
bacteria
gramneg
bacteria
fungi
respect
inappropri
empir
antibiot
therapi
administ
event
kaplanmei
curv
show
signific
differ
patient
inappropri
empir
antibiot
therapi
appropri
therapi
logrank
test
p
univari
analysi
show
inappropri
empir
antibiot
therapi
hazard
ratio
confid
interv
p
age
hazard
ratio
confid
interv
p
deescal
therapi
hazard
ratio
confid
interv
p
associ
factor
mortal
multivari
cox
regress
analysi
show
inappropri
empir
antibiot
therapi
independ
risk
factor
mortal
hazard
ratio
confid
interv
p
adjust
mccabe
sever
assess
score
conclus
inappropri
empir
antibiot
therapi
independ
risk
factor
mortal
pediatr
patient
bloodstream
infect
os
acut
gastroenter
hospit
children
southern
taiwan
emphasi
clostridium
difficil
relat
acut
gastroenter
fuchun
kuo
shihmin
wang
chingfen
shen
ning
chung
tzongshiann
ho
chingchuan
liu
tpida
